NCT04848220View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

August 23, 2022

Study Completion Date

August 31, 2022

Conditions
Microvascular Obstruction
Interventions
DRUG

Temanogrel

Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)

DRUG

Placebo

Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1

Trial Locations (12)

2050

Royal Prince Alfred Hospital, Camperdown

2139

Concord Repatriation General Hospital, Concord

3004

Alfred Health - The Alfred Hospital, Melbourne

6000

Royal Perth Hospital, Perth

60637

University of Chicago Medical Center, Chicago

94304

VA Palo Alto - Cardiac Catheterization Laboratory, Palo Alto

90822-5201

Tibor Rubin VA Medical Center, Long Beach

6525 GA

Radboud University Medical Center, Nijmegen

3079 DZ

Maasstad Hospital, Rotterdam

5623 EJ

Catharina Ziekenhuis, Eindhoven

221 85

Skåne University Hospital, Lund

SG1 4AB

East and North Hertfordshire NHS Trust Lister Hospital, Stevenage

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arena is a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Pfizer

INDUSTRY

NCT04848220 - A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter